BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33331926)

  • 1. Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations.
    Miao H; Kim E; Chen D; Purohit T; Kempinska K; Ropa J; Klossowski S; Trotman W; Danet-Desnoyers G; Cierpicki T; Grembecka J
    Blood; 2020 Dec; 136(25):2958-2963. PubMed ID: 33331926
    [No Abstract]   [Full Text] [Related]  

  • 2. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
    Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting FLT3 for the treatment of leukemia.
    Small D
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S17-21. PubMed ID: 18760705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.
    Weisberg E; Liu Q; Nelson E; Kung AL; Christie AL; Bronson R; Sattler M; Sanda T; Zhao Z; Hur W; Mitsiades C; Smith R; Daley JF; Stone R; Galinsky I; Griffin JD; Gray N
    Leukemia; 2012 Oct; 26(10):2233-44. PubMed ID: 22469781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
    Knapper S; Russell N; Gilkes A; Hills RK; Gale RE; Cavenagh JD; Jones G; Kjeldsen L; Grunwald MR; Thomas I; Konig H; Levis MJ; Burnett AK
    Blood; 2017 Mar; 129(9):1143-1154. PubMed ID: 27872058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.
    Uras IZ; Walter GJ; Scheicher R; Bellutti F; Prchal-Murphy M; Tigan AS; Valent P; Heidel FH; Kubicek S; Scholl C; Fröhling S; Sexl V
    Blood; 2016 Jun; 127(23):2890-902. PubMed ID: 27099147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will newer tyrosine kinase inhibitors have an impact in AML?
    Levis MJ
    Best Pract Res Clin Haematol; 2010 Dec; 23(4):489-94. PubMed ID: 21130412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.
    Grunwald MR; Levis MJ
    Int J Hematol; 2013 Jun; 97(6):683-94. PubMed ID: 23613268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
    Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.
    Sternberg DW; Licht JD
    Curr Opin Hematol; 2005 Jan; 12(1):7-13. PubMed ID: 15604885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
    Jeon JY; Zhao Q; Buelow DR; Phelps M; Walker AR; Mims AS; Vasu S; Behbehani G; Blachly J; Blum W; Klisovic RB; Byrd JC; Garzon R; Baker SD; Bhatnagar B
    Invest New Drugs; 2020 Apr; 38(2):340-349. PubMed ID: 31102119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
    Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
    Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
    Daver N; Venugopal S; Ravandi F
    Blood Cancer J; 2021 May; 11(5):104. PubMed ID: 34045454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Future of Targeting FLT3 Activation in AML.
    Leick MB; Levis MJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
    Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE
    Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.
    Larrosa-Garcia M; Baer MR
    Mol Cancer Ther; 2017 Jun; 16(6):991-1001. PubMed ID: 28576946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
    Stone RM; Mandrekar SJ; Sanford BL; Laumann K; Geyer S; Bloomfield CD; Thiede C; Prior TW; Döhner K; Marcucci G; Lo-Coco F; Klisovic RB; Wei A; Sierra J; Sanz MA; Brandwein JM; de Witte T; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Krauter J; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Larson RA; Döhner H
    N Engl J Med; 2017 Aug; 377(5):454-464. PubMed ID: 28644114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
    Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
    Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming Resistance to FLT3 Inhibitors in the Treatment of
    Lam SSY; Leung AYH
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.